United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cisco Systems

Chevron

Dow Inc

Coca-Cola

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

Walgreens

Exxon Mobil

With 2019 coming to a rapid end, it’s important to reflect on what happened in the past year.

Meet the Preliminary 2020 Dogs of the Dow

AbbVie

Allergan

Bristol-Myers

Celgene

Eli Lilly

Medicines

Merck

Novartis

Sanofi

Mergers and acquisitions have lit up biotech stocks, and the hot pace shows no sign of slowing in 2020. Gene therapy and oncology companies are targets.

Biotech Stocks Burn A Hole In Big Pharma's Pocket. Look For More In 2020

YONKERS, N.Y., Dec.  10, 2019  (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatment of life-threatening infectious diseases, today announced the pricing of its underwritten public offering of 37,150,000 shares of its common stock at a public offering price of $0.27 per share. The gross proceeds from the public offering will be approximately $10 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by ContraFect.  In addition, ContraFect also announced that Pfizer Inc. has agreed to purchase 11,111,111 shares of ContraFect’s common stock pursuant to a stock purchase agreement with ContraFect at the price per share in the public offering, in a separate private placement transaction that is expected to close concurrently with the public offering. The gross proceeds from the private placement will be $3 million.  All shares in the public offering and private placement are to be sold by ContraFect. 

ContraFect Corporation Prices Approximately $10 Million Public Offering of Common Stock and Concurrent $3 Million Private Placement of Common Stock to Pfizer

Pfizer (NYSE: PFE) spends nearly twice the money on selling, general & administrative (SG&A) expenses than it does on research & development (R&D). SG&A Accounted for 34% of the company’s total expenditure in 2018, while it was 19% for R&D.This can partly be attributed to the promotional expenses.

Pfizer Spending Twice As Much On Selling Than Research?

Which stock wins in a matchup between these two big drugmakers?

Better Buy: Pfizer vs. Bristol-Myers Squibb

Accenture Plc

Walmart

These stalwart stocks span retail, cloud computing, and healthcare.

3 Dividend Stocks  You Can Safely Hold for Decades

Amgen

Which of these pharma giants is the better buy?

Better Buy: Amgen vs. Pfizer

Pfizer stock has tumbled, below other pharmaceutical stocks. Recent news has been upbeat with a drug approval and acquisitions.

Pfizer Stock Is A Top Pharma Company — But Should You Buy It?

Pfizer (PFE)/Astellas' Xtandi gets approval in China to treat metastatic castration-resistant prostate cancer (CRPC).

Pfizer/Astellas Xtandi Gets Nod in China for Prostate Cancer (Revised)

JPMorgan Chase & Co

The eight “Dogs of the Dow” for 2019 have an aggregate year-to-date gain of 9.2% at the end of November.

How To Trade The ‘Dogs Of the Dow’ In December

GlaxoSmithKline

Roche Holding AG

Large-Cap Pharmaceuticals Industry Prospects Bright for 2020

Pfizer (PFE) reported earnings 30 days ago. What's next for the stock?

Why Is Pfizer (PFE) Up 0.4% Since Last Earnings Report?

Eleven drugmakers led by Pfizer and Novartis have set aside a combined $2 billion to invest in gene therapy manufacturing since 2018, according to a Reuters analysis, in a drive to better control production of the world's priciest medicines.

Pfizer, Novartis lead $2 billion spending spree on gene therapy production

Teva Pharmaceutical

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials.

Big Pharma Short Sellers Hike Their Bets

Pfizer/Astellas Xtandi Gets Nod in China for Prostate Cancer

Pfizer, Novartis lead pharma spending spree on gene therapy production

Pfizer: Grab The Popcorn, Wait And See

Which of these pharma titans is the better buy right now?

Better Buy: Eli Lilly (LLY) vs. Pfizer (PFE)

Pfizer’s(NYSE: PFE) Rheumatoid Arthritis drug ~ Xeljanz ~ is a relatively small drug with sales of around $2 billion, and it accounts for around 4% of the total rheumatoid arthritis drugs market. AbbVie’s Humira is the leader based on drug’s total sales.

Pfizer’s Xeljanz In the Crowded Rheumatoid Drugs Market

The approval of Humira biosimilar is the fourth U.S. approval of a biosimilar product for Pfizer (PFE) in 2019.

Pfizer Gets FDA Approval for Biosimilar of AbbVie's Humira

Pfizer (PFE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

How Pfizer (PFE) Stock Stands Out in a Strong Industry

Johnson & Johnson

Drug stocks have been out of favor due to regulatory concerns. Nevertheless, several top-tier stock experts and contributors to MoneyShow.com see select opportunities for long-term value investors to consider buying large cap pharmaceutical names.

Out-of-Favor Drugs Stocks May be the Right Medicine For Your Portfolio

Snap

Splunk

Friday's 3 big stock charts highlight 3 names looking for help from a market at all-time highs.
The post 3 Big Stock Charts for Friday: Snap, Pfizer and Splunk appeared first on InvestorPlace.

3 Big Stock Charts for Friday: Snap, Pfizer and Splunk

Biogen

DaVita

Edwards Lifesciences

HCA Healthcare

Incyte

Teleflex

Health Care Select Sector SPDR Fund

DENTSPLY SIRONA

These are the health care stocks with the best value, fastest growth, and most momentum for November.

Top Health Care Stocks for November 2019

News for Pfizer Stock (PFE)